Pasithea Therapeutics Corp. — Director's Dealing 2023

Jun 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2023-06-02

Reporting Person: STEINMAN LAWRENCE (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-02	Common Stock	P	30000	$0.431	Acquired	1327174	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.38 to $0.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.